Journal Mobile Options
Table of Contents
Vol. 215, No. 4, 2007
Issue release date: October 2007
Dermatology 2007;215:295–300
(DOI:10.1159/000107622)

Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy

Passarini B. · Infusino S.D. · Barbieri E. · Varotti E. · Gionchetti P. · Rizzello F. · Morselli C. · Tambasco R. · Campieri M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Ulcerous rectocolitis and Crohn’s disease are the best known forms of inflammatory bowel disease (IBD). Skin manifestations are not uncommon in IBD and may be divided into specific cutaneous signs, aspecific cutaneous signs, and cutaneous signs caused by drugs used for IBD therapy. The specific signs (fistulas, rhagades and ulcers) are the result of the diffusion of the intestinal inflammatory process into the skin. Aspecific cutaneous signs (stomatic aphthosis, erythema nodosum, pyoderma gangrenosum, Sweet’s syndrome, vasculitis, bullous diseases) are quite frequently found in those suffering from IBD, but also in apparently healthy subjects, and may sometimes be the first sign of the intestinal disease. Cutaneous manifestations due to drugs vary in clinical aspect and are the direct consequence of the therapies adopted, which in IBD patients can be quite numerous: steroids, immunosuppressants, 5-aminosalicylic acid, biological agents, antibiotics. Objective and Methods:Due to the frequent finding of cutaneous manifestations in patients affected by IBD, a collaboration was set up between the Dermatological Clinic of the University of Bologna and the Center for the Study of IBD of the same university hospital. The aim was to diagnose the cutaneous signs appearing during IBD and to establish their etiopathogenesis in order to assess whether they were the result of epiphenomena of the IBD or side effects of the therapies adopted. Results: The cutaneous manifestations we observed can be divided into three distinct groups: signs that were specific to the basic disease, aspecific signs and finally signs attributable to the drugs used for therapy. Particular attention was given to the aspecific signs and those consequential to therapy. The aspecific cutaneous signs seen in our clinic generally reflect those reported in the literature. The cutaneous manifestations due to drugs were further divided into three groups: rosacea, acneiform dermatitis and psoriasis-like dermatitis. The most notable aspect of our series is the high number of patients presenting psoriasiform-type dermatitides with a generally widespread diffusion. Conclusion: We would like to draw attention to the fact that all patients with psoriasis had been undergoing treatment with drugs inhibiting tumor necrosis factor α (TNF-α) as part of IBD therapy. In all cases, the cutaneous reaction started after the third or fourth infusion of the biological drug. Anti-TNF-α agents have also been successfully used to treat psoriasis in the last few years. The reason for this apparently paradoxical effect of the therapy is still unclear.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Voigtlander V, Maaben D: Manifestazioni cutanee in corso di malattie internistiche. Rome, Micarelli, 1997, pp 98–108.
  2. Trost LB, McDonnel JK: Important cutaneous manifestation of inflammatory bowel disease. Postgrad Med J 2005;81:580–585.
  3. Laungani AG, Khandelwal A, Tomecki KJ: A young woman with an eroded plaque on the hand. Cleve Clin J Med 2006;73:369–371.
  4. Requena L, Requena C: Erythema nodosum. Dermatol Online J 2002;8:4.

    External Resources

  5. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995;131:48–52.
  6. Tavadia SM, Smith G, Herd RM, Zuk RJ: Sweet’s syndrome associated with oral squamous cell carcinoma and exhibiting the Koebner phenomenon. Br J Dermatol 1999; 141:169–170.
  7. Watts RA, Jolliffe VA, Grattan CE, Elliott J, Lockwood M, Scott DG: Cutaneous vasculitis in a defined population: clinical and epidemiological associations. J Rheumatol 1998;25:920–924.
  8. Mendoza JL, Garcia-Paredes J, Pena AS, Cruz-Santamaria DM, Iglesias C, Diaz Rubio M: A continuous spectrum of neutrophilic dermatoses in Crohn’s disease. Rev Esp Enferm Dig 2003;95: 229–236.
  9. Cruz A, Vazquez Botet M: Papulopustular eruption in intestinal inflammatory disease. Med Cutan Ibero Lat Am 1989;17:343–347.
  10. Crowson AN, Nuovo GJ, Mihm MC Jr, Magro C: Cutaneous manifestations of Crohn’s disease, its spectrum, and its pathogenesis: intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn’s disease. Hum Pathol 2003;34:1185–1192.
  11. Fellermann K, Rudolph B, Witthoft T, Herrlinger KR, Tronnier M, Ludwig D, Stange EF: Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus. Med Klin (Munich) 2001;15:105–108.

    External Resources

  12. Arai S, Katsuoka K: Cutaneous manifestations with ulcerative colitis. Nippon Rinsho 1999;57:2571–2574.
  13. Kano Y, Shiohara T, Yagita A, Nagashima M: Erythema nodosum, lichen planus and lichen nitidus in Crohn’s disease: report of a case and analysis of T cell receptor V gene expression in the cutaneous and intestinal lesions. Dermatology 1995;190:59–63.
  14. Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, Griga T: Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001;39:37–44.

    External Resources

  15. Yates VM, Watkinson G, Kelman A: Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol 1982;106:323–330.
  16. Thielen AM, Barde C, Janer V, Borradori L, Saurat JH: Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease. Br J Dermatol 2007;156:188–189.
  17. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor-necrosis-factor-alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 2006;213:182–186.
  18. Thurber M, Feasel A, Stroehlein J, Hymes SR: Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439–440.

    External Resources

  19. Lowes MA, Turton JA, Krueger JG, Barnetson RS: Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 2005;5:9.
  20. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ: Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol 2004;151:506–507.
  21. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A: Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513–2518.
  22. Beuthien W, Mellinghoff HU, Von Kempis J: Skin reaction to adalimumab. Arthritis Rheum 2004;50:1690–1692.
  23. Grinblat B, Scheinberg M: Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 2004;50:1690–1692.
  24. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666–R676.
  25. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, Ständer E, Maass U, Lee H, Sterry W, Burmester GR: New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists. Ann Rheum Dis 2006;65:405–407 (comment in Ann Rheum Dis 2006;65:1680).
  26. Haibel H, Spiller I, Strasser C: Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-α blocking agents: four case reports (abstract SAT0061). EULAR 2004, Berlin, June 9–12, 2004.
  27. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM: Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829–834.
  28. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E: Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54–57.
  29. Michaëlsson G, Kajermo U, Michaëlsson A, Hagforsen E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-α in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1243–1244.
  30. Peramiquel L, Puig L, Dalmau J, Ricart E, Roe E, Alomar A: Onset of flexural psoriasis during infliximab treatment for Crohn’s disease. Clin Exp Dermatol 2005;30:713–714.
  31. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829–830.
  32. Weisenseel P, Prinz JC: Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 2006;78:197–199.
  33. Vena GA, Cassano N: Emerging drugs for psoriasis. Expert Opin Emerg Drugs 2006;11:567–596.
  34. Altomare G: A proposito dei biofarmaci anti-TNF-α: gioie e dolori. Psoriasis 2006;1:37–40.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50